Immune booster shows promise in fighting dangerous fungal infection

NCT ID NCT04979052

Completed Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested whether adding interferon-gamma to standard antifungal treatment helps clear Candida from the blood faster. 65 adults with candidemia received the drug or standard care alone. The study is completed, and results will show if this combination is safe and speeds up recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Interferon gamma-1b (Immukin)
What this could lead to: If it works, this could offer a way to help the immune system fight Candida bloodstream infections more quickly, reducing hospital stays.
What could go wrong: This is an early Phase 2 trial with only 65 participants, so results may not apply to everyone. Adding an immune booster may also cause side effects like fever or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANDIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

candidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANDIDEMIA

Contacts and locations

Locations

Centre Hospitalier Universitaire Vaudois

Lausanne, 1005, Switzerland
Duke University

Durham, North Carolina, 27708, United States
Hellenic Institute for the Study of Sepsis (HISS)

Athens, 11528, Greece
Klinikum Der Johann Wolfgang Von Goethe Universitaet

Frankfurt am Main, 60590, Germany
Radboudumc

Nijmegen, Gelderland, 6525 GA, Netherlands
Universitatea de Medicina si Farmacie luliu Hatieganu

Cluj-Napoca, 400348, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.